View in EDS HTML Full Text PDF Full Text

Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence-authors' reply.

Saved in:
Bibliographic Details
Title: Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence-authors' reply.
Authors: Visuri I; Örebro, Sweden., Eriksson C; Örebro, Sweden.; Stockholm, Sweden., Olén O; Stockholm, Sweden., Cao Y; Örebro, Sweden., Mårdberg E; Örebro, Sweden., Grip O; Malmö, Sweden., Gustavsson A; Karlstad, Sweden., Hjortswang H; Linköping, Sweden., Karling P; Umeå, Sweden., Montgomery S; Örebro, Sweden.; Stockholm, Sweden., Myrelid P; Linköping, Sweden., Ludvigsson JF; Örebro, Sweden.; Stockholm, Sweden., Halfvarson J; Örebro, Sweden.
Source: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2021 Sep; Vol. 54 (6), pp. 848-849.
Publication Type: Editorial; Comment
Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8707234 Publication Model: Print Cited Medium: Internet ISSN: 1365-2036 (Electronic) Linking ISSN: 02692813 NLM ISO Abbreviation: Aliment Pharmacol Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1365-2036
DOI:10.1111/apt.16569